Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (not Altery Therapeutics Ltd) covers the month of November 2006. The registrant is an Australian biotechnology company headquartered in South Melbourne, Victoria. The filing reports a change in the interests of a substantial holder pursuant to the Corporations Act 2001.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice regarding shareholding changes and does not contain financial statements or operational metrics.
Material Changes Versus Prior Period
The filing details a change in the voting power of substantial holder Baywick Pty Ltd due to the dilution from the issue of new shares:
- Previous Voting Power: 13.44% (17,055,000 votes).
- Present Voting Power: 11.84% (17,055,000 votes).
- Nature of Change: Dilution due to the issue of new Prana Biotechnology Limited (PBT) shares.
- Consideration: None given in relation to this specific change.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for management guidance, future outlook, specific risks, contingencies, or unusual items. The document is strictly a statutory notice of a change in substantial holding.
Important Facts for Investor Verification
- Verify the total number of issued shares post-dilution to confirm the 11.84% voting power calculation.
- Confirm the identity of the substantial holder, Baywick Pty Ltd (ACN 007 226 708), and its relationship to the company.
- Note that the substantial holder's absolute vote count remained constant at 17,055,000, indicating the change was purely percentage-based due to capital raising or share issuance.
- Check for subsequent filings to see if Baywick Pty Ltd has adjusted its position following this dilution event.